

HFA Atrial Disease Workshop

Focus on Atrial Fibrillation_Heart Failure co-treatment

A joint Initiative of HFA Committees on Co-morbidities, the Translational Research Committee, the Committee on Surveys, Registries and Epidemiology, Committee of HFpEF and the Committee on Cardiomyopathies of the Heart Failure Association.

Date: 24-25 April 2018 – Lunch to lunch

Location: Zürich – Romantik Seehotel Sonne - Seestrasse 120 – 8700 Küsnacht am Zürichsee, Zürich Switzerland

Coordinators: Andrew Coats, Frank Ruschitzka, Lars Lund, Rudolf de Boer and Stephane Heymans.

Participants:

Coordinators: Andrew **Coats** (UK), Frank **Ruschitzka** (CH), Lars **Lund** (SW), Rudolf **de Boer** (NL), Stephane **Heymans** (NL).

Stefan Anker (DE)	Alexander Lyon (UK)
Johannes Backs (DE)	Jan Steffel (CH)
Johann Bauersachs (DE)	Aristomenis Manouras (SE)
Jelena Celutkiene (LT)	Davor Milicic (CR)
John Cleland (UK)	Christian Müller (CH)
Dobromir Dobrev (DE)	Marija Polovina (RS)
Gerasimos Filippatos (GR)	Giuseppe Rosano (UK/IT)
Gerhard Hindricks (DE)	Petar Seferovic (RS)
Ewa Jankowska (PL)	Carsten Tschöpe (DE)
Dipak Kotecha (UK)	Isabelle Van Gelder (NL)
Mitja Lainscak (SI)	Linda Van Laake (NL)
Celine Linde (SE)	Rolf Wachter (DE)
Ida Gjervold Lunde (NO)	

Medical writer – Dimitrios **Farmakis** (GR)

Day 1, Tuesday April 24th 2018

Chairman of the Meeting: Frank Ruschitzka

14.00 – 14.05 Welcome on behalf of the HFA

F. Ruschitzka (CH)

14:05 – 14:10 Welcome from our EHRA Colleagues

G. Hindricks (DE)

14.10 – 14.20 Introduction and aims

A. Coats (UK) S. Heymans (NL)

Background: atrial fibrillation and heart failure

Chairperson G. Rosano (UK), S. Heymans (NL)

14:20 – 14:35 Epidemiology (Common risk factors, prognosis)

D. Kotecha (UK)

14:35 – 14:50 Overview of common basic mechanisms: differences between atria and ventricles.

D. Dobrev (DE)

14:50 – 15:05 Lone AF does not exist

I. Van Gelder (NL)

15:05 – 15:20 Discussion

Discussants (without additional presentation)

L. Lund (SE), A. Coats (UK)

Basic mechanisms

Chairpersons J. Bauersachs (DE), L. Van Laake (NL)

15:20 – 15:40 Imaging of the left Atrium

J. Celutkiene (LT)

15:40 – 15:50 Atrial remodeling and fibrosis – lessons from ALDO-DHF

R. Wachter (DE)

15:50 – 16:00 Atrial remodeling and LA strain – lessons from KaRen
16:00 – 16:20 Discussion

A. Manouras (SE)

Discussants (without additional presentation)

I. Lunde (NO), J. Backs (DE)

16:20 – 16:50 Coffee break

Upstream therapy of AF and HF

Chairperson G. Hindricks, A. Coats

16:50 – 17:05 Basic Mechanisms: how existing drugs would work?

C. Tschöpe

17:05 – 17:20 Clinical studies: rhythm or rate control?

I. Van Gelder (NL)

17:20 – 17:35 Clinical studies: pace or ablate

G. Hindricks (DE)

17:35 – 17:50 Discussion

Discussant (leading the discussion without additional presentation)

Christian Müller (CH)

Discussion: Other anti-fibrotics?

Other pleiotropic effects of AA? Inflammation? Endothelial?

Need for new clinical trials co-treatment AF_HF with AA?

17:50 – 18:20 General discussion, focusing on the following questions:

1. Is there any such thing as a separate combined AF-HF phenotype?
2. Which are the common mechanisms of atrial fibrillation and heart failure?
3. Anything such as co-treatment of AF and HF (PEF)?
4. What can we learn from the AF ablation trials in HFrEF?
5. Which drugs were successful for treating both HF and AF?
6. Future: separate drugs versus AF_HF co-treatments?

Dinner at 19:30 at the hotel restaurant.

Day 2, Wednesday 25th of April

Oral anti-coagulants (NOACs) in AF (hypercoagulability)

Chairpersons J. Backs (DE), E. Jankowska (PL)

08:30 – 08:50 Sources and Mechanisms of stroke in AF

J. Steffel (CH)

08:50 – 09:10 NOAC's clinical studies: HF outcome

G. Rosano (UK)

09:10 – 09:40 Discussion

Discussants (without additional presentation)

G. Rosano (IT/UK)

Marija Polovina (RS)

Treatment of atrial myopathy

Chairpersons R. De Boer (NL), A. Coats (UK)

09:40 – 10:00 Atrial myopathy in the absence of AF: treatment?

C. Tschöpe (DE)

10:00 – 10:20 Atrial myopathy in the presence of AF: treatment?

John Cleland (UK)

10:20 – 10:40 Discussion

Discussants (without additional presentation)

Jelena Celutkiene (LT)

Mitja Lainscak (SI)

10:40 – 11:10 Coffee break

Future research to better treat AF and HF together

Chairpersons A. Coats (UK), G. Filippatos (GR)

11:10 – 11:30 Basic research perspective

R. de Boer (NL)

11:30 – 11:50 HFA trialist perspective

S. Anker (DE)

11:50 – 12:10 EHRA trialist perspective

G. Hindricks (DE)

12:00 – 12:30 General discussion, covering the following topics:

1. Which drugs were failures, which ones look promising?
2. What is special about specific drugs?
3. How can drug discovery targeting diabetes and metabolic diseases help in finding cures for AF_heart failure treatment?
4. Which research aims would we set out for the next 5-10 years, both clinically and basic/mechanistically?
5. Could the creation of inter-therapy working groups help?

Lunch (12:30) - adjourn